Market›Health Care›Biotechnology›Biotechnology
BRAINSTORM CELL THER

BCLI

$0.77Apr 26, 2021 – Apr 24, 2026
Health CareBiotechnology$10M
MVM
+$0.2M
TD Variance
2.454

Every news event mapped to its market reaction — 94 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2023-03-30+33.2%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2025-07-17-30.5%newsSeeking AlphaBrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down
2025-07-17-30.5%newsInvesting.comBrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com
2024-04-01+29.4%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$0.40 beats by $0.16
2024-04-01+29.4%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2024-04-09-16.9%legalSeeking AlphaBrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy
2024-04-09-16.9%legalSEC EDGARBCLI 8-K: 8.01 and (SEC Filing)
2026-02-13-16.0%legalSEC EDGARBCLI 8-K: 1.01, 3.02 (SEC Filing)
2026-02-20+15.1%newsPR NewswireBrainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
2026-02-20+15.1%legalSeeking AlphaBrainstorm Cell secures $1M strategic financing
2026-02-20+15.1%newsPR NewswireBrainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market - PR Newswire
2025-05-15+14.7%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$0.45 beats by $0.52
2025-05-15+14.7%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2026-02-26+13.9%legalPR NewswireBrainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
2022-11-14+13.8%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2023-11-22+13.2%legalSEC EDGARBCLI 8-K: 8.01 and (SEC Filing)
2025-03-27-12.7%legalSEC EDGARBCLI 8-K: 8.01 (SEC Filing)
2024-06-27-12.6%newsSeeking AlphaBrainStorm Cell Therapeutics announces pricing of $4M registered direct offering
2026-02-19+12.5%newsGlobeNewswireGlobal Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
2025-06-25-12.2%newsSeeking AlphaBrainStorm finalizes prior offering
2025-06-25-12.2%legalSEC EDGARBCLI 8-K: 5.02, 5.07 (SEC Filing)
2025-07-19-12.1%newsTradingViewBCLI Stock Price and Chart — OTC:BCLI - TradingView
2023-06-20-10.4%legalSEC EDGARBCLI 8-K: 5.02 and (SEC Filing)
2025-04-24+9.8%newsStock TitanBCLI Stock Price, News & Analysis | Brainstorm Cell Therapeutics I - Stock Titan
2025-11-14+8.9%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$0.19
2025-11-14+8.9%legalSEC EDGARBCLI 8-K: 1.01, 2.02, 3.02 (SEC Filing)
2025-11-14+8.9%newsPR NewswireBrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
2024-09-26-8.6%legalSEC EDGARBCLI 8-K: 8.01 (SEC Filing)
2024-07-08-8.3%newsSeeking AlphaIPO Roundup: Actuate Therapeutics, Autozi Internet, and more
2024-07-08-8.3%newsSeeking AlphaBrainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)
2025-06-16+8.1%legalSEC EDGARBCLI 8-K: 8.01 and (SEC Filing)
2024-06-26-8.0%legalSEC EDGARBCLI 8-K: 8.01 and (SEC Filing)
2023-11-14-7.4%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2023-01-04-7.4%legalSEC EDGARBCLI 8-K: 1.01, 5.02 (SEC Filing)
2024-09-16-7.3%legalSEC EDGARBCLI 8-K: 5.02, 5.03, 5.07 (SEC Filing)
2022-05-16+6.8%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2024-06-20-6.8%executiveSeeking AlphaBrainStorm appoints Haro Hartounian as COO
2024-06-20-6.8%legalSEC EDGARBCLI 8-K: 5.02 and (SEC Filing)
2022-09-22+6.5%legalSEC EDGARBCLI 8-K: 1.01, 5.02 (SEC Filing)
2021-12-17+6.4%legalSEC EDGARBCLI 8-K: 5.02 and 5.07 (SEC Filing)
2024-04-02-6.2%legalSEC EDGARBCLI 8-K: 1.01 and (SEC Filing)
2022-08-27-6.0%analystZacks Investment ResearchWhat is the current Price Target and Forecast for Brainstorm Cell Therapeutics (BCLI) - Zacks Investment Research
2025-05-19-5.8%expansionSeeking AlphaBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans
2025-05-19-5.8%earningsSeeking AlphaBrainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript
2025-05-19-5.8%legalSEC EDGARBCLI 8-K: 8.01 and (SEC Filing)
2026-03-31+5.5%newsPR NewswireBrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
2026-03-31+5.5%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$1.11 beats by $0.50
2026-03-31+5.5%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2026-03-31+5.5%newsPR NewswireBrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update - PR Newswire
2026-03-31+5.5%newsStock TitanBrainStorm Cell (OTCQB: BCLI) posts 2025 loss, tight cash and equity deficit - Stock Titan
2024-11-14+5.3%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$1.80
2024-11-14+5.3%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2025-03-28-5.3%earningsSeeking AlphaBrainStorm Cell Therapeutics Q4 2024 Earnings Preview
2023-10-24-5.2%legalSEC EDGARBCLI 8-K: 2.05, 5.02, 7.01 (SEC Filing)
2024-08-14-5.2%earningsSeeking AlphaBrainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript
2024-08-14-5.2%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$0.04 in-line
2024-08-14-5.2%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2023-05-24-5.1%legalSEC EDGARBCLI 8-K: 5.02 (SEC Filing)
2025-08-13-5.1%earningsSeeking AlphaBrainStorm Cell Therapeutics Q2 2025 Earnings Preview
2024-08-13+4.9%earningsSeeking AlphaBrainStorm Cell Therapeutics Q2 2024 Earnings Preview
2023-07-19-4.8%legalSEC EDGARBCLI 8-K: 1.01, 8.01 (SEC Filing)
2025-03-26-4.8%newsSeeking AlphaBrainStorm Cell Therapeutics receives Nasdaq compliance extension
2025-05-14-4.7%earningsSeeking AlphaBrainStorm Cell Therapeutics Q1 2025 Earnings Preview
2023-12-20-4.5%legalSEC EDGARBCLI 8-K: 5.07, 7.01, 8.01 (SEC Filing)
2025-08-14-4.3%earningsSeeking AlphaBrainstorm Cell Therapeutics outlines readiness for Phase IIIb ALS trial as funding and regulatory developments shape next steps
2025-08-14-4.3%earningsSeeking AlphaBrainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript
2025-08-14-4.3%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$0.77
2025-08-14-4.3%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2025-08-14-4.3%legalPR NewswireBrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
2021-08-25-4.3%legalSEC EDGARBCLI 8-K: 5.02 (SEC Filing)
2021-08-05+4.2%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2022-03-28-3.4%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2024-10-30-3.3%newsSeeking AlphaBrainStorm Cell Therapeutics regains compliance with Nasdaq
2023-08-14-3.1%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2024-04-17-3.0%executiveSeeking AlphaBrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer
2024-04-17-3.0%legalSEC EDGARBCLI 8-K: 5.02, 8.01 (SEC Filing)
2024-05-15+3.0%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$0.05 beats by $0.02
2026-01-09+2.8%legalSEC EDGARBCLI 8-K: 1.01, 3.02 (SEC Filing)
2024-04-11-2.7%legalSEC EDGARBCLI 8-K: 8.01 and (SEC Filing)
2022-08-15-2.3%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2026-02-27+1.9%legalSEC EDGARBCLI 8-K: 1.01, 3.02, 5.02 (SEC Filing)
2023-05-15-1.8%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2022-01-28+1.8%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2021-10-29+1.7%legalSEC EDGARBCLI 8-K: 5.02 and (SEC Filing)
2025-11-06+1.0%legalSEC EDGARBCLI 8-K: 1.01, 3.02 (SEC Filing)
2025-03-31-1.0%earningsSeeking AlphaBrainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript
2025-03-31-1.0%earningsSeeking AlphaBrainStorm Cell Therapeutics GAAP EPS of -$2.31
2025-03-31-1.0%legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
2025-03-31-1.0%legalSEC EDGARBCLI 8-K: 1.01, 3.02 (SEC Filing)
2021-05-28-0.4%legalSEC EDGARBCLI 8-K: 5.02 (SEC Filing)
2022-10-12+0.3%legalSEC EDGARBCLI 8-K: 7.01, 8.01 (SEC Filing)
2024-06-28+0.2%legalSEC EDGARBCLI 8-K: 1.01, 3.02, 8.01 (SEC Filing)
2026-04-24—newsStockInvest.usBrainstorm Cell Therapeutics Stock Price Forecast. Should You Buy BCLI? - StockInvest.us
2021-04-26—legalSEC EDGARBCLI 8-K: 2.02 and (SEC Filing)
tickerdossier.comtickerdossier.substack.com